The potential tumor suppressor antizyme and its endogenous inhibitor (antizyme inhibitor, AZI) have been implicated in the ubiquitin-independent proteasomal degradation of proteins involved in cell proliferation as well as in the regulation of polyamine levels. We show here that both antizyme and AZI concentrate at centrosomes and that antizyme preferentially associates with the maternal centriole. Interestingly, alterations in the levels of these proteins have opposing effects on centrosomes. Depletion of antizyme in various cell lines and primary cells leads to centrosome overduplication, whereas overexpression of antizyme reduces numerical centrosome abnormalities. Conversely, silencing of the antizyme inhibitor, AZI, results in a decrease of numerical centrosome abnormalities, whereas overexpression of AZI leads to centrosome overduplication. We further show that the numerical centrosome abnormalities are due to daughter centriole amplification. In summary, our results demonstrate that alterations in the antizyme/AZI balance cause numerical centrosomal defects and suggest a role for ubiquitin-independent proteasomal degradation in centrosome duplication.
Introduction
Antizymes were first studied with regard to their role in regulating the activity and stability of the rate-limiting enzyme in polyamine biosynthesis, ornithine decarboxylase (ODC) (Coffino, 2001) . Antizymes comprise an ancient gene family and antizyme-mediated, ubiquitinindependent proteasomal protein degradation is highly conserved from yeast to humans. The most abundant and best characterized family member is antizyme 1. Antizyme 1 binds ODC with high affinity, thereby blocking its enzymatic activity and promoting the ubiquitin-independent degradation of ODC via the 26S proteasome (Murakami et al., 1992) . Today, its role is seen in a considerably broader context, as antizyme 1 has been shown to affect the stability of several additional proteins such as cyclin D1 and Smad1 (Lin et al., 2002; Newman et al., 2004) . Since elevated ODC activity is associated with most forms of human malignancies (Gerner and Meyskens, 2004) , it was suggested early on that antizyme 1 may function as a tumor suppressor. Supporting this hypothesis, it has been shown that antizyme 1 overexpression leads to cell cycle arrest, apoptosis and reduced cell proliferation in vitro, (Iwata et al., 1999; Koike et al., 1999) and inhibits tumor growth in several mouse models in vivo (Iwata et al., 1999; Tsuji et al., 2001; Fong et al., 2003) .
Antizymes themselves are negatively regulated by a protein referred to as the antizyme inhibitor (AZI). AZI is highly homologous to ODC but lacks its enzymatic activity (Murakami et al., 1996) . Reduced AZI expression leads to inhibition of cell proliferation (Choi et al., 2005; Kim et al., 2006) and recent data suggest a possible correlation between AZI and malignancy (Jung et al., 2000; Keren-Paz et al., 2006; Kim et al., 2006) . In summary, antizyme 1 and AZI act together to regulate ubiquitin-independent degradation of proteins that modulate polyamine metabolism and cell proliferation.
Centrosome defects, chromosomal instability and cytological changes occur in the earliest identifiable steps of human cancer (Meraldi and Nigg, 2002) . Centrosome amplification and aneuploidy are common events triggered by the loss of tumor suppressors or by overexpression of oncogenes. The accuracy of centrosome duplication is therefore essential for maintenance of genomic stability and centrosome duplication is coupled to the cell division cycle (D'Assoro et al., 2002; Doxsey et al., 2005; Fukasawa 2005; Sluder 2005; Nigg 2006 ; Tsou and Stearns, 2006) .
Recent evidence has shown that many components of the proteasomal degradation machinery concentrate at centrosomes and form active proteasomal complexes (Fabunmi et al., 2000; Andersen et al., 2003) . We show here that antizyme 1, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor, AZI, localize to centrosomes and are functionally important centrosome-associated proteins. In addition, altered levels of antizyme 1 and AZI rapidly affect centriole amplification suggesting that these proteins may contribute to oncogenesis in part through disregulation of centrosome homeostasis.
Results
Centrosomal localization of antizyme 1 and its endogenous inhibitor (AZI) Several components of the ubiquitin-dependent degradation pathway concentrate at the centrosome. Therefore, we were interested to investigate whether antizyme 1 and AZI, which are involved in ubiquitin-independent proteasomal degradation, may also localize to centrosomes and affect centrosomal function. We first employed immunofluorescence staining for antizyme 1 in various mouse, rat and human cell lines. As seen in Figure 1a , we detected colocalization of the antizyme 1 signal with the centrosomal marker g-tubulin. Interestingly, the centrosomal antizyme 1 signal was only detected during interphase. Treatment with the microtubule-depolymerizing drug nocodazole did not displace the centrosomal antizyme 1 signal demonstrating that the localization of antizyme 1 is microtubule independent (Supplementary data S1). In addition to its centrosomal localization, antizyme 1 was also detected in the nucleus (Figures 1a and d and Supplementary data S1) as reported previously (Murai et al., 2003) . The nuclear localization of antizyme 1 was, however, only detected in a fraction of U2OS and NIH-3T3 cells (Figures 1a and d) . Centrosomal localization of antizyme 1 was also detected by immunoblot analysis of centrosomal fractions prepared from non-synchronized U2OS cells. As seen in Figure 1b , antizyme 1 cofractionated with the centrosomal marker protein g-tubulin. The existence of two antizyme 1 bands has been reported previously and represents initiation at the first and second AUG codon of the open reading frame 1 of antizyme 1 (Mitchell et al., 1998) . To confirm further the specificity of the centrosomal antizyme 1 signal, we established U2OS cells with stable expression of green fluorescent protein (GFP)-antizyme 1. Immunostaining for GFP and g-tubulin showed colocalization of the two signals ( Figure 1c ). Taken together, these data clearly indicate that antizyme 1 localizes to centrosomes in mammalian cells. (c) GFP-tagged antizyme 1 localizes to centrosomes. U2OS cells stably overexpressing GFP-antizyme 1 were plated on coverslips, fixed with methanol and stained for GFP. Centrosomes were visualized using an antibody against g-tubulin. Nuclei were stained with DAPI. Bar ¼ 10 mm. (d) Colocalization of antizyme 1 with the primary cilium. NIH-3T3 cells were plated on coverslips and grown in 0.5% bovine calf serum (BCS) (serum starvation) for 48 h. Cells were then fixed and costained for antizyme 1 and acetylated a-tubulin. Nuclei were stained with DAPI. Bars ¼ 10 mm. DAPI, 4
0 ,6-diamidino-2-phenylindole; GFP, green fluorescent protein.
Strikingly, a preferential localization of antizyme 1 with one of the two centrioles was repeatedly noticed (Figure 1a ). During mitosis, cells inherit one pair of centrioles that contains the older 'maternal' centriole and the younger 'daughter' centriole. One marker for the maternal centriole is the primary cilium (Lange and Gull, 1995) . It can be induced in NIH-3T3 cells by serum starvation and contains acetylated a-tubulin. As seen in Figure 1d , the antizyme 1 signal colocalizes with the centriole that carries the primary cilium. We did not, however, observe a preferential association of GFP-antizyme with one centriole which might be due to non-physiological expression of the fusion protein. Consistent with previous reports (Murai et al., 2003) , the GFP-antizyme 1 signal was otherwise mostly cytoplasmic and not nuclear.
Next, we wished to investigate whether the known antizyme inhibitor, AZI, also localizes to centrosomes. We therefore employed immunofluorescence staining for AZI in various mouse, rat and human cell lines as well as in primary human keratinocytes. As shown in Figures  2a and d , AZI and the centrosomal marker protein pericentrin colocalize. AZI also localized to the nucleus and Golgi in human cells such as U2OS, HUVEC and primary foreskin fibroblasts (Figure 2a and data not shown). This is reminiscent of other centrosomal proteins such as g-tubulin and centrin for which non-centrosome-associated localization has also been reported.
Centrosomal AZI localization was also observed using a rabbit polyclonal antibody, raised against a C-terminal peptide of AZI (Supplementary data S2). The specificity of the AZI staining was further confirmed by a competition study (Supplementary data S3) and later by a strong reduction of the centrosomal AZI staining in AZI-siRNA-treated cells (Figure 4b ). In addition, we detected AZI by immunoblot analysis in centrosomal fractions derived from U2OS cells with stable overexpression of centrin-GFP. As seen in Figure 2b , AZI cofractionated with two centrosomal markers, g-tubulin and centrin. We also analysed the centrosome-containing sucrose gradient fraction 4 for g-tubulin and AZI. As shown in Figure 2c , fraction 4 contains intact centrosomes that stain for both g-tubulin and AZI.
We next analysed the centrosomal localization of AZI in NIH-3T3 cells throughout the cell cycle. AZI localized to centrosomes at every phase of the cell cycle ( Figure 2d ). The staining pattern was very similar to that of the pericentriolar marker protein pericentrin. Treatment with the microtubule-depolymerizing drug nocodazole did not displace the centrosomal AZI signal demonstrating that, similar to antizyme 1, centrosomal AZI localization is independent of microtubule dynamics (Supplementary data S4).
Finally, we performed immunogold electron microscopy for AZI in U2OS cells to specify further its centrosomal localization. As seen in Figure 2e , AZI shows a pericentriolar localization and is closely associated with both the mother and daughter centriole during interphase. No staining was observed with protein A gold alone.
Modulation of the antizyme 1/AZI balance causes numerical centrosome abnormalities
To evaluate a potential centrosomal function of antizyme 1 and AZI, we reduced their protein expression levels using siRNA. We first silenced antizyme 1 in NIH-3T3 and AT2.1 cells using two different siRNAs, AZ-a and AZ-b (Figure 3a) . Each siRNAs caused a strong downregulation of antizyme 1 protein expression, as quantified by Scion imaging software (75-90% reduction). We next examined whether silencing of antizyme 1 affects centrosomes by staining for g-tubulin. Normal cells never exhibit more than two g-tubulin dots at any stage of the cell cycle (Supplementary data S5). As shown in Figure 3b , antizyme 1 depletion caused a significant increase of cells with abnormal g-tubulin dot numbers (4.7-5.6-fold; P ¼ 0.002, NIH-3T3; 2.4-fold; P ¼ 0.001, AT2.1).
Next, we wanted to determine whether primary human cells also display centrosome abnormalities when antizyme 1 levels are altered. We therefore silenced antizyme 1 in primary human keratinocytes. Reverse transcription-PCR (RT-PCR) analysis revealed that antizyme 1 was efficiently silenced in two sets of keratinocytes ( Figure 3c ). After 48 h of siRNA treatment, the reduction of antizyme 1 levels correlated with increased numbers of cells with supernumerary g-tubulin dots (Figures 3d and e) . Taken together these results suggest an important role for antizyme 1 in modulating centrosome numbers in normal human cells.
We next investigated whether depletion of AZI also affects centrosome function. AZI was silenced in AT2.1 and U2OS cells by two different sets of siRNAs (AZI-139 and AZI-pool). A non-specific scrambled siRNA was used as control (SCR). As confirmed by immunoblot analysis, each siRNA caused a marked reduction in AZI protein levels (Figure 4a ). Immunofluorescence microscopy also demonstrated that the centrosomal AZI staining was strongly reduced in cells transfected with AZI-specific siRNA (Figure 4b ).
Consistent with published reports (Meraldi et al., 1999; Habedanck et al., 2005) , cell lines, such as U2OS and AT2.1, display a background of 6-8% of cells with numerical centrosome abnormalities. AZI depletion caused a significant decrease (2.8-fold; P ¼ 0.002, U2OS; 15.8-fold; P ¼ 0.0003, AT2.1) in cells with more than two g-tubulin dots (Figure 4c ). Hence, interfering with AZI activity can reduce numerical centrosome abnormalities in tumor cells.
Since silencing of AZI also inhibits cell proliferation, we tested whether AZI depletion directly inhibits centrosome duplication or if this effect was secondary to the inhibition of cell cycle progression. To address this issue, we used an experimental approach described by Zou et al. (2005) . Treatment with hydroxyurea (HU) leads to cell cycle arrest in S phase and causes centriole overamplification in certain cell lines such as U2OS (Meraldi et al., 1999) . If the effect of AZI depletion on centrosome numbers resulted from a G 1 /S arrest, then AZI-siRNA would be effective only if it were administered to cells before HU treatment. If, however, AZI has a direct role in centriole duplication, then AZI-siRNA is expected to inhibit centriole duplication even when administered after HU-mediated S-phase arrest. As shown in Figure 4d , treatment with AZI-siRNA reduced centrosome abnormalities regardless of whether AZIsiRNA was administered to U2OS cells before or after the HU treatment. Hence, AZI affects centriole duplication independent of its role in cell cycle progression.
We next investigated the consequence of antizyme 1 overexpression on centrosome abnormalities and generated U2OS clones with stable expression of Centrosomal role of antizyme and AZI U Mangold et al GFP-antizyme 1. U2OS cells were chosen because they have intact pRb and p53 pathways and have been extensively used for studies with centrosomes (Meraldi et al., 1999; Habedanck et al., 2005) . The N-terminal GFP tag did not interfere with the ability of antizyme 1 to bind AZI (Supplementary data S6). GFP-antizyme 1 expression was verified by immunoblotting (Figure 5a ). Interestingly, we also observed an increase of endogenous AZI in the GFP-antizyme 1-overexpressing cells ( Figure 5a ). As shown in Figure 5b , antizyme 1-overexpressing cells showed a 2.3-to 4.5-fold decrease in centrosome abnormalities when compared to cells that overexpress GFP alone (P ¼ 0.0002 and 0.00001). No difference was observed between GFP overexpressing and U2OS wild-type cells (compare Figures 5b and 4c ).
Next we wished to determine whether ectopic AZI expression also affects centrosome abnormalities. We established U2OS clones with stable expression of GFP-AZI. The N-terminal GFP tag did not interfere with the ability of AZI to bind antizyme 1 (Supplementary data S6). Overexpression of GFP-AZI was confirmed by immunoblotting ( Figure 6a ). Consistent with antizyme inhibition by GFP-AZI, each of the three AZI overexpressing clones showed elevated levels of two known antizyme target proteins, ODC and cyclin D1 (Figure 6a ).
As seen in Figure 6b , AZI overexpressing cells showed a significant increase in centrosome abnormalities when compared to control cells that stably overexpressed GFP alone (P ¼ 0.00006). In addition to g-tubulin, these dots also stained positive for centrin, pericentrin and AZI (Figure 6c ). With regard to antizyme 1, we frequently detected preferential staining associated with one of the dots within a cluster (Figure 6c ). Together these results suggest important opposing roles for antizyme 1 and AZI in modulating centrosome homeostasis independent of cell cycle progression.
AZI overexpression results in daughter centriole amplification
We next wanted to investigate whether the numerical centrosome abnormalities observed in AZI-overexpressing cells are caused by aberrant synthesis of daughter centrioles or are the result of cytokinesis defects. To address this question we determined the ratio of mother and daughter centrioles. Ninein was used as a specific marker for maternal centrioles and centrin was used as a general centriole marker. Cells that have accumulated abnormal centriole numbers as a consequence of cytokinesis failure contain a normal ratio of maternal and daughter centrioles. In contrast, aberrant daughter centrioles that arise through a mechanism independent of cytokinesis failure should lead to cells with more than four centrioles but not more than 1 or 2 maternal centrioles. As shown in Figure 6d , we observed excess daughter centrioles in the AZI overexpressing cells Centrosomal role of antizyme and AZI U Mangold et al without additional maternal centrioles. We further quantified the AZI-overexpressing cells for their mother to daughter centriole ratio and confirmed that the centrosome abnormalities were primarily due to daughter centriole overduplication (Figure 6e) . Consistent with our model that antizyme 1 and AZI affect centriole homeostasis through a common mechanism, siRNAmediated antizyme 1 depletion in NIH-3T3 cells also caused accumulation of excess daughter centrioles (Supplementary data S7).
We next examined the AZI overexpressing cells during mitosis to assess whether the extra daughter centrioles fully mature and produce functionally active mitotic spindle poles. We observed that the majority of aberrant mitotic cells (B90%) did not display multipolar spindles. Instead, we found that the extra centrioles either failed to form spindle poles or were clustered together at either one or both spindle poles leading to bipolar spindle formations (Figure 6f) . Costaining of g-tubulin with a-tubulin showed that these extra centrioles are not major contributors to the microtubule organizing center of the spindle (Figure 6f) .
Finally, we assessed the ploidy status of AZI-overexpressing cells by flow cytometry. The DNA content of two independent AZI-overexpressing clones was analysed and proved to be indistinguishable from that of wild-type U2OS cells (Figure 6g ). Together, our results demonstrate that the observed centrosome abnormalities of the AZI-overexpressing cells are not the result of cytokinesis defects, but rather the consequence of aberrant daughter centriole synthesis.
Discussion
In this study, we show that antizyme 1, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor AZI are components of the centrosome, and that they play an important role in the regulation of centrosome homeostasis.
To date, partial centrosome localization has been shown for several proteins involved in ubiquitination and proteasomal degradation (Fabunmi et al., 2000; Andersen et al., 2003) . We now show that a fraction of antizyme 1 associates with maternal centrioles and modulates daughter centriole amplification. Consistently, it has been reported that antizyme 1 activity peaks during the G 1 /S phase of the cell cycle (Oredsson, 2003) when synthesis and maturation of centrioles occurs. Taken together, these results suggest the possibility that the stability of certain centriole components may be regulated through ubiquitin-independent proteasomal degradation. We cannot, however, conclude from our results that the effect of antizyme 1 can be attributed solely to the fraction that associates with the centrosome. The extra-centrosomal antizyme 1 pools might contribute to this effect as well.
Downregulation of antizyme inhibitor activity is associated with reduced cell proliferation (Choi et al., 2005; Kim et al., 2006) . Moreover, overexpression of AZI increases cell proliferation and promotes cell transformation (Keren-Paz et al., 2006; Kim et al., 2006) and high levels of AZI have been observed in gastric tumors (Jung et al., 2000) . Our results show that overexpression of AZI induces aberrant synthesis of daughter centrioles as reported previously for the papillomavirus-16 E7 oncoprotein (Guarguaglini et al., 2005) . We have now identified AZI overexpression as an alternative cause for daughter centriole overamplification again suggesting that the antizyme 1/AZI system regulates centriole synthesis. Our results also show that AZI overexpression leads to significantly higher levels of cyclin D1 and ODC whose stability are both regulated by antizyme 1 (Murakami et al., 1992; Newman et al., 2004) . Overexpression of cyclin D1 has been reported to induce centrosome abnormalities, but it led to hyperamplification of centrosomes with equal numbers of daughter and mother centrioles (Nelsen et al., 2005) . Hence it is unlikely that the antizyme 1/AZI system regulates centrosome homeostasis through cyclin D1. To address the possibility that regulation of ODC levels and activity may contribute to the centrosome-related activities of antizyme 1/AZI, we also investigated whether inhibition of ODC activity through the specific and irreversible ODC inhibitor difluoromethylornithine (DFMO) may affect centrosome homeostasis. At a DFMO concentration that has been shown to reduce ODC activity without substantial cytostatic activity (Kim et al., 2006) , ODC inhibition did not affect centrosome abnormalities (data not shown). This indicates that inhibition of polyamine biosynthesis may not be the principal mechanism by which antizyme 1 and AZI regulate centrosome homeostasis.
Hence we hypothesize that antizyme 1 has additional, as yet unknown targets and may regulate the stability of important centrosomal components. Interestingly, it has been recently reported that the Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through a proteasome-dependent but ubiquitin-independent pathway (Lim and Gopalan, 2007) demonstrating that the stabilities of centrosomeassociated proteins can be mediated through ubiquitinindependent proteasomal degradation.
In summary, our results demonstrate that loss of antizyme 1 activity through silencing or overexpression of AZI induces aberrant synthesis of daughter centrioles. We therefore propose the hypothesis that antizyme 1 contributes to the proteasomal turnover of a critical regulator of daughter centriole synthesis and suggest a novel role for the antizyme 1/AZI system in tumorigenesis.
Materials and methods
Cell culture and transfection Primary human foreskin keratinocytes (HFK) were grown in serum-free medium (Keratinocyte-SFM, Invitrogen, Carlsbad, CA, USA). U2OS and U2OS-GFP-centrin cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% glutamine-penicillin-streptomycin (GPS). HFK cells were transfected using the neonatal keratinocyte nucleofactor kit (Amaxa, Gaithersburg, MD, USA). Stable U2OS transfectants were generated with Lipofectamine 2000 (Invitrogen) and were selected in G418 (700 mg/ml) for 2 weeks.
siRNA transfection
The siRNAs were delivered into cells using Lipofectamine 2000. The siRNAs targeting AZI were rat/mouse AAGAUC-GUGAAGAAGCACAGU (AZI-139) and AZI Smartpool (Dharmacon, Lafayette, CO, USA). The siRNAs targeting rat/ mouse antizyme 1 were AACAGUCAGCGGGAUCACAGU (AZ-a) and AACCUUCAGCUUUCUUGGCUU (AZ-b). The siRNA targeting human antizyme 1 was Smartpool antizyme 1. The control siRNA was scramble II Duplex (Dharmacon).
Antibodies and immunoblot analysis
Primary antibodies were antizyme rabbit serum (1:1000; gift of Dr J Mitchell); AZI mouse monoclonal (1:2000; gift of Dr S Matsufuji), GFP (1:1000; Molecular Probes/Invitrogen), g-tubulin (1:2000; GTU-88; Sigma, St Louis, MO, USA), cyclin D1 (1:250; G124-326; BD Biosciences, San Jose, CA, USA), ODC (1:500; Progen), actin (1:10 000; C4; Chemicon). Secondary antibodies were peroxidase-conjugated anti-rabbit or anti-mouse (1:10 000; Pierce, Rockford, IL, USA).
Immunofluorescence microscopy Primary antibodies were mouse monoclonal AZI (1:1000; gift of Dr S Matsufuji) rabbit polyclonal AZI (1:200, affinity purified), rabbit polyclonal antizyme 1 serum (1:25; gift of Dr J Mitchell), g-tubulin (1:400, GTU-88; Sigma), pericentrin (1:500; Covance), ninein (1:500; Abcam), centrin (1:1000, 20H5; gift of Dr Salisbury), a-tubulin (1:500; Abcam) acetylated a-tubulin (1:200, 6-11B-1; Zymed) diluted in 1% bovine serum albumin/phosphate-buffered saline. All secondary antibodies were Alexa Fluor 488 or 568 (Molecular Probes).
RT-PCR
Total RNA was isolated from human primary keratinocytes transfected with siRNA using the RNeasy Mini kit (Qiagen, Valencia, CA, USA). Human antizyme 1 mRNA levels were assayed by RT-PCR using the SuperScript III first-strand synthesis system for RT-PCR (Invitrogen). PCR primers for human antizyme 1 were Fwd1 5 0 -CAGCAGCAGTGA GAGTTCCAG-3 0 and Rev1 5 0 -GGAGCAAGGCGG CTCTGT-3 0 .
Statistical methods
The mean percentage and s.d. of two to three independent experiments with at least 100-200 cells evaluated per experiment are given unless indicated otherwise. Two-tailed Student's t-test was used where applicable. Additional information relating to Materials and methods is found in the Supplementary Information.
